吉西他滨单药治疗多线化疗后晚期结直肠癌的临床效果

Clinical Effect of Gemcitabine Monotherapy in the Treatment of Advanced Colorectal Cancer After Multi-Line Chemotherapy

目的评价吉西他滨单药对多线化疗后晚期结直肠癌的近期疗效。方法选取2016年6月至2019年5月新乡市中心医院/新乡医学院第四临床学院收治的28例多线化疗后晚期结直肠癌患者,均接受吉西他滨单药化疗,每例患者完成2个周期以上化疗(2~6个周期)。结果所有患者均可进行疗效评价,其中部分缓解(PR)2例,疾病稳定(SD)16例,完全缓解(CR)0例。客观缓解率(ORR)为7.14%,疾病控制率(DCR)为64.29%,中位无进展生存期(PFS)为3.7个月,中位总生存期(OS)为10.6个月。不良反应主要为骨髓抑制和消化道反应,仅2例患者因重度骨髓抑制推迟用药。结论吉西他滨单药化疗方案对多线化疗后晚期结直肠癌患者DCR高,且不良反应可耐受。

Objective To evaluate the short-term efficacy of gemcitabine monotherapy in the treatment of advanced colorectal cancer after multi-line chemotherapy.Methods A total of 28 patients with advanced colorectal cancer after multi-line chemotherapy who were admitted to Xinxiang Central Hospital/the Fourth Clinical College of Xinxiang Medical University from June 2016 to May 2019 were selected.All the patients were treated with gemcitabine monotherapy,and each patient completed more than 2 cycles of chemotherapy(2 to 6 cycles).Results All the patients were available for evaluation.Of the 28 patients,2 cases had partial response(PR),and 16 cases had stable disease(SD),and no complete response(CR)case occured.The objective response rate(ORR)was 7.14%,and the disease control rate(DCR)was 64.29%.The median progression-free survival(PFS)was 3.7 months,and the median overall survival(OS)was 10.6 months.The main adverse reactions were myelosuppression and gastrointestinal reaction.Only two cases were delayed due to severe myelosuppression.Conclusion Gemcitabine monotherapy has a high DCR in patients with advanced colorectal cancer after multi-line chemotherapy,and the adverse reactions are tolerable.